UA104426C2 - Протипухлинні ефекти комбінацій канабіноїдних сполук - Google Patents

Протипухлинні ефекти комбінацій канабіноїдних сполук

Info

Publication number
UA104426C2
UA104426C2 UAA201015971A UAA201015971A UA104426C2 UA 104426 C2 UA104426 C2 UA 104426C2 UA A201015971 A UAA201015971 A UA A201015971A UA A201015971 A UAA201015971 A UA A201015971A UA 104426 C2 UA104426 C2 UA 104426C2
Authority
UA
Ukraine
Prior art keywords
tumoural
cannabinoid combinations
effects
cancer
cannabinoid
Prior art date
Application number
UAA201015971A
Other languages
English (en)
Russian (ru)
Inventor
Дієс Гільєрмо Веласко
Пастор Мануель Гусман
Мар Лоренте
Софія Торрес
Фатіма Родрігес
Original Assignee
Джидаблю Фарма Лімітед
Оцука Фармасьютікал Ко Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA104426(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джидаблю Фарма Лімітед, Оцука Фармасьютікал Ко Лімітед filed Critical Джидаблю Фарма Лімітед
Publication of UA104426C2 publication Critical patent/UA104426C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)

Abstract

Винахід належить до галузі медицини та фармацевтики і стосується комбінації канабіноїдів тетрагідроканабінолу (ТГК) і канабідіолу (КБД) в співвідношенні від 5:1 до 1:5 для застосування в лікуванні пухлини головного мозку, більш конкретно гліоми, ще більш конкретно мультиформної гліобластоми (МГБ).
UAA201015971A 2008-06-04 2009-06-04 Протипухлинні ефекти комбінацій канабіноїдних сполук UA104426C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0810195.8A GB2471987B (en) 2008-06-04 2008-06-04 Anti-tumoural effects of cannabinoid combinations
PCT/GB2009/050621 WO2009147439A1 (en) 2008-06-04 2009-06-04 Anti-tumoural effects of cannabinoid combinations

Publications (1)

Publication Number Publication Date
UA104426C2 true UA104426C2 (uk) 2014-02-10

Family

ID=39638149

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201015971A UA104426C2 (uk) 2008-06-04 2009-06-04 Протипухлинні ефекти комбінацій канабіноїдних сполук

Country Status (21)

Country Link
US (4) US8632825B2 (uk)
EP (2) EP3785710A1 (uk)
JP (1) JP5611196B2 (uk)
KR (2) KR101801639B1 (uk)
CN (1) CN102083430B (uk)
AR (1) AR072003A1 (uk)
AU (1) AU2009254936B2 (uk)
BR (1) BRPI0913384A2 (uk)
CA (1) CA2726258C (uk)
CO (1) CO6382172A2 (uk)
GB (1) GB2471987B (uk)
IL (1) IL209738B (uk)
MX (1) MX2010012557A (uk)
MY (1) MY156444A (uk)
NZ (1) NZ589228A (uk)
RU (1) RU2546284C2 (uk)
SG (2) SG191644A1 (uk)
TW (1) TWI445531B (uk)
UA (1) UA104426C2 (uk)
WO (1) WO2009147439A1 (uk)
ZA (1) ZA201008556B (uk)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2494461A (en) 2011-09-12 2013-03-13 Gw Pharma Ltd Phytocannabinoids for use in the treatment of invasive cancers or metastases
GB201117956D0 (en) 2011-10-18 2011-11-30 Otsuka Pharma Co Ltd Phytocannabinoids for use in the treatment of breast cancer
EP2719375A1 (en) * 2012-10-10 2014-04-16 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Cannabinoids for the treatment of cancers dependent on hedgehog mechanisms
CA2895805A1 (en) 2012-12-18 2014-06-26 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
GB2516814B (en) * 2013-06-19 2016-08-31 Otsuka Pharma Co Ltd Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
EP3552482B1 (en) 2013-10-29 2022-06-29 Biotech Institute, LLC Breeding, production, processing and use of specialty cannabis
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CN114191420A (zh) * 2014-05-29 2022-03-18 雷迪厄斯制药公司 稳定的大麻素类化合物制剂
GB2527590A (en) 2014-06-27 2015-12-30 Otsuka Pharma Co Ltd Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer
WO2016054268A1 (en) 2014-09-30 2016-04-07 MJAR Holdings, LLC Methods of growing cannabaceae plants using artificial lighting
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
EP3067058A1 (en) 2015-03-13 2016-09-14 Farmagens Health Care Srl Biological composition based on engineered lactobacillus paracasei subsp. paracasei f19 for the biosynthesis of cannabinoids
CN107846861A (zh) 2015-05-28 2018-03-27 推德有限公司 Thca合成酶表达改变的大麻植物
US10123973B2 (en) * 2015-06-11 2018-11-13 Mashhad University Of Medical Science Liposome composition for cancer treatment
EP3307266A4 (en) * 2015-06-11 2019-01-16 One World Cannabis Ltd Novel CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM)
CA2993023C (en) * 2015-07-22 2020-04-28 Phytopharma International Ltd. Bee-ingestible compositions, methods of using same for producing honey and honey produced thereby
US9572783B1 (en) 2015-10-08 2017-02-21 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
EP3153160B1 (en) 2015-10-08 2021-08-11 Chuen Wei Lu Use of xanthophylls for the treatment of cancers
KR20180102053A (ko) * 2015-10-27 2018-09-14 제이 파마 인코포레이티드 칸나비다이올 및 제2 치료제를 포함하는, 암을 치료하기 위한 조성물
AU2016359160A1 (en) 2015-11-24 2018-06-14 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
AU2018233582B2 (en) * 2017-03-16 2022-04-07 CannTab Therapeutics, Limited Modified release multi-layer tablet cannabinoid formulations
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
WO2019227167A1 (en) * 2018-06-01 2019-12-05 The University Of Sydney Compositions and treatments
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
WO2020129043A1 (en) * 2018-12-19 2020-06-25 Pathway RX Inc. Novel cannabis sativa lines and extracts with anti-cancer properties
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
IL272078A (en) * 2020-01-16 2021-07-29 Can Fite Biopharma Ltd Cannabinoids for use in therapy
CN111773390B (zh) * 2020-07-01 2021-08-20 南京大学 一种药物在制备治疗脑转移瘤及其相关疾病的药品中的应用
WO2022225658A1 (en) * 2021-04-19 2022-10-27 The Regents Of The University Of California Cannabis limits cancer stem cell growth in poorly differentiated cancers
WO2023062634A1 (en) * 2021-10-13 2023-04-20 G.R.I.N Ultra Ltd Compositions comprising cannabinoids and methods of use thereof in the treatment of cancer
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566560B2 (en) * 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES1045342Y (es) 2000-02-11 2001-02-16 Alvarez Manuel Couto Expositor giratorio para postales, fotos y similares.
ES2164584A1 (es) * 2000-02-11 2002-02-16 Univ Madrid Complutense Terapia con cannabinoides para el tratamiento de tumores cerebrales.
US20040039048A1 (en) * 2000-02-11 2004-02-26 Manuel Guzman Pastor Therapy with cannabinoid compounds for the treatment of brain tumors
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
AU2001290949A1 (en) * 2000-09-14 2002-03-26 California Pacific Medical Center Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
US20080057117A1 (en) 2002-02-15 2008-03-06 Forschungs Institut Miscia Verenfur Krebsforschung Pharmaceutical composition made up of cannibus extracts
IL148244A0 (en) 2002-02-19 2002-09-12 Yissum Res Dev Co Anti-nausea and anti-vomiting activity of cannabidiol compounds
AU2002326312A1 (en) * 2002-04-25 2003-11-10 Virginia Commonwealth University Cannabinoids
US6946150B2 (en) * 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
GB2394894B (en) 2002-11-04 2005-08-31 G W Pharma Ltd New use for pharmaceutical composition
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
GB2418612A (en) * 2004-10-01 2006-04-05 Gw Pharma Ltd Inhibition of tumour cell migration with cannabinoids
EP1907444B1 (en) 2005-04-01 2009-08-19 Intezyne Technologies Incorporated Polymeric micelles for drug delivery
US7968594B2 (en) * 2005-04-27 2011-06-28 Gw Pharma Limited Pharmaceutical compositions for the treatment of pain
CA2608399A1 (en) * 2005-05-13 2006-11-23 Unimed Pharmaceuticals, Inc. Dronabinol treatment of delayed chemotherapy-induced nausea and vomiting
GB2448535A (en) * 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) * 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2471987B (en) 2008-06-04 2012-02-22 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2460672B (en) * 2008-06-04 2012-01-04 Gw Pharma Ltd Cannabinoids in combination with non-cannabinoid chemotherapeutic agents that are alkylating agents

Also Published As

Publication number Publication date
KR20110051179A (ko) 2011-05-17
RU2546284C2 (ru) 2015-04-10
AU2009254936A1 (en) 2009-12-10
EP3785710A1 (en) 2021-03-03
TWI445531B (zh) 2014-07-21
JP5611196B2 (ja) 2014-10-22
AR072003A1 (es) 2010-07-28
IL209738A0 (en) 2011-02-28
MX2010012557A (es) 2011-02-15
JP2011522029A (ja) 2011-07-28
MY156444A (en) 2016-02-26
CA2726258A1 (en) 2009-12-10
US20140287067A1 (en) 2014-09-25
US8632825B2 (en) 2014-01-21
CO6382172A2 (es) 2012-02-15
IL209738B (en) 2018-10-31
RU2010153576A (ru) 2012-07-20
GB2471987B (en) 2012-02-22
CN102083430B (zh) 2015-10-07
US20110117216A1 (en) 2011-05-19
BRPI0913384A2 (pt) 2020-08-04
KR20160103148A (ko) 2016-08-31
AU2009254936B2 (en) 2015-03-19
US20200138771A1 (en) 2020-05-07
KR101801639B1 (ko) 2017-12-28
CA2726258C (en) 2017-09-12
NZ589228A (en) 2013-05-31
WO2009147439A1 (en) 2009-12-10
US20150313867A1 (en) 2015-11-05
GB0810195D0 (en) 2008-07-09
ZA201008556B (en) 2014-11-26
SG191644A1 (en) 2013-07-31
SG195650A1 (en) 2013-12-30
EP2318000A1 (en) 2011-05-11
TW201002315A (en) 2010-01-16
GB2471987A (en) 2011-01-19
CN102083430A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
UA104426C2 (uk) Протипухлинні ефекти комбінацій канабіноїдних сполук
MY156264A (en) Cannabinoids in combination with non-cannabinoid chemotherapeutic agents (e.g serm or alkylating agents)
NZ602953A (en) Phytocannabinoids in the treatment of cancer
MX2014002873A (es) Fitocanabinoides que pueden usarse en el tratamiento del cancer.
EA201290975A8 (ru) Применение фитоканнабиноида каннабидиварина (cbdv) для лечения эпилепсии
IN2012DN02018A (uk)
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
CO6670568A2 (es) Métodos de terapia combinada para tratar enfermedades profilerativas
EP4140487A8 (en) Combination therapy for treating cancer
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2009016488A3 (en) Compositions comprising tetracyclic antidepressants for treatment of cancer and related methods
CO6731081A2 (es) Método para producir y usar un copolímero de carboximetilcelulosa sódica y gosipol
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
MX2015007280A (es) Terapia de combinacion para cancer.
WO2014074765A3 (en) Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
WO2011089531A3 (en) Effects of the association of vitamin k2 and vitamin d3 in the consolidation of a bone fracture
WO2008106606A3 (en) Carotenoid analogs and derivatives in the treatment of prostate cancer
TH137276B (th) "ไฟโตแคนนาบินอยด์ในการรักษามะเร็ง"
TH137276A (th) ไฟโตแคนนาบินอยด์ในการรักษามะเร็ง
TH124701A (th) ผลในการต่อต้านเนื้องอกของสารผสมรวมแคนนาบินอยด์
UA29209U (uk) Спосіб хірургічного лікування раку молочної залози
MA31958B1 (fr) Composition a base de plantes medicinales pour le traitement des cancers
UA37591U (uk) Спосіб комбінованого лікування гліом головного мозку
UA36366U (uk) Спосіб лікування катаральної форми епіглотиту із ознаками несприятливого перебігу та некротичної форми епіглотиту